Kayne Anderson Rudnick Investment Management
IMCR icon

Kayne Anderson Rudnick Investment Management’s Immunocore IMCR Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3
Closed – – 692
2021
Q4 		$0 Buy
+3
New +$109 ﹤0.01% 646

Other funds holding IMCR

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's IMCR Position: Q1 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Immunocore (IMCR) in Q1 2022, closing a stake of 3 shares.

Kayne Anderson Rudnick Investment Management first reported a position in IMCR in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 57 funds tracked by Wall St. Rank hold IMCR as of Q1 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Immunocore position as of Q1 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 3 Immunocore shares in Q1 2022.
  • Kayne Anderson Rudnick Investment Management first reported a position in Immunocore in Q4 2021 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Immunocore position peaked at $0 in Q4 2021.
  • 57 funds tracked by Wall St. Rank held Immunocore as of Q1 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q1 2022, filed 16 May 2022.